Prestige Consumer Healthcare Inc. (PBH)
- Previous Close
69.67 - Open
69.94 - Bid --
- Ask --
- Day's Range
69.50 - 70.84 - 52 Week Range
52.90 - 75.31 - Volume
338,783 - Avg. Volume
248,817 - Market Cap (intraday)
3.466B - Beta (5Y Monthly) 0.53
- PE Ratio (TTM)
-- - EPS (TTM)
-1.61 - Earnings Date May 2, 2024 - May 6, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date Dec 27, 2013
- 1y Target Est
75.60
Prestige Consumer Healthcare Inc., together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare. It offers BC/Goody's analgesic powders, Boudreaux's Butt Paste baby ointments, Chloraseptic sore throat liquids and lozenges, Clear Eyes for eye redness relief, Compound W wart removals, DenTek for PEG oral care, Debrox ear wax removals, and Dramamine for motion sickness relief. The company also provides Fleet adult enemas/suppositories, Gaviscon upset stomach remedies, Luden's cough drops, Monistat vaginal anti-fungal, Nix lice/parasite treatments, Summer's Eve feminine hygiene, TheraTears dry eye relief, Fess nasal saline spray and washes, and Hydralyte for oral rehydration products. It sells its products through mass merchandisers; and drug, food, dollar, convenience, and club stores, as well as e-commerce channels. The company was formerly known as Prestige Brands Holdings, Inc. and changed its name to Prestige Consumer Healthcare Inc. in August 2018. Prestige Consumer Healthcare Inc. was founded in 1996 and is headquartered in Tarrytown, New York.
www.prestigebrands.com560
Full Time Employees
March 31
Fiscal Year Ends
Sector
Recent News: PBH
Performance Overview: PBH
Trailing total returns as of 4/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: PBH
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: PBH
Valuation Measures
Market Cap
3.47B
Enterprise Value
4.62B
Trailing P/E
--
Forward P/E
15.20
PEG Ratio (5yr expected)
1.90
Price/Sales (ttm)
3.06
Price/Book (mrq)
2.17
Enterprise Value/Revenue
4.07
Enterprise Value/EBITDA
429.26
Financial Highlights
Profitability and Income Statement
Profit Margin
-7.11%
Return on Assets (ttm)
6.16%
Return on Equity (ttm)
-4.91%
Revenue (ttm)
1.13B
Net Income Avi to Common (ttm)
-80.67M
Diluted EPS (ttm)
-1.61
Balance Sheet and Cash Flow
Total Cash (mrq)
63.62M
Total Debt/Equity (mrq)
75.82%
Levered Free Cash Flow (ttm)
175.69M
Research Analysis: PBH
Company Insights: PBH
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: PBH
PBH: Lowering target price to $71.00
PRESTIGE CONSUMER HEALTHCARE has an Investment Rating of HOLD; a target price of $71.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetPBH: Raising target price to $73.00
PRESTIGE CONSUMER HEALTHCARE has an Investment Rating of HOLD; a target price of $73.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetPBH: Rating increased to a HOLD
PRESTIGE CONSUMER HEALTHCARE has an Investment Rating of HOLD; a target price of $56.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetPBH: Lowering target price to $58.00
PRESTIGE CONSUMER HEALTHCARE has an Investment Rating of SELL; a target price of $58.000000; an Industry Subrating of Low; a Management Subrating of Medium; a Safety Subrating of Medium; a Financial Strength Subrating of Medium; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target